-+ 0.00%
-+ 0.00%
-+ 0.00%

ABBVIE - RISANKIZUMAB IN ULCERATIVE COLITIS SHOWS CLINICAL REMISSION RATES OF 54.0%-73.1% AT WEEK 96

路透·10/17/2026 06:03:27

請登錄查看新聞詳情